A phase I dose-escalation study of BIBH-1 [sibrotuzumab I-131] in patients with advanced or metastatic fibroblast activation protein-positive cancer
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2013
At a glance
- Drugs Sibrotuzumab I-131 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 17 Dec 2009 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2005 New trial record.